News

ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker Study

CHARLOTTESVILLE, VA Apr. 21, 2021 -- ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study. ValenzaBio is deploying Ready to
Continue Reading

New Playbooks Authored by ArcheMedX Explore Digital Transformation in Clinical Trials

ArcheMedX, a leader in behavior-based learning and operational insights for life sciences organizations, announced the release of two new whitepaper companions to its recent report, “COVID-19's Impact on Virtual Tech in Clinical Trials.” These whitepapers, focused on clinical research organizations and clinical trial sponsors, respectively, are intended to be playbooks
Continue Reading

New ArcheMedX Report “COVID-19’s Impact on Virtual Tech in Clinical Trials” Reveals Changing Priorities for Sponsors, CROs in a Remote World

Today, ArcheMedX, a leader in behavior-based learning and operational insights for life sciences and healthcare organizations, announced the results of its new survey, “COVID-19's Impact on Virtual Tech in Clinical Trials.” The findings reveal brand-new insights into how clinical trial leaders in pharmaceuticals, biotech, and clinical research organizations are accelerating
Continue Reading